Investors in the healthcare sector often find themselves navigating turbulent waters, especially when stock prices dip. However, some companies continue to provide dividends that reward shareholders while they await a market recovery. This article highlights three healthcare companies that not only weather the storm but also offer attractive dividend yields.
Medtronic: Resilience Through Innovation
Medtronic, a leader in medical technology, operates in critical sectors such as cardiovascular care, neuroscience, and diabetes management. Despite facing challenges, including a significant stock price decline of over 35% in the past five years, Medtronic has managed to maintain a strong revenue stream. In the fiscal third quarter of 2026, the company reported $9 billion in revenue, marking an 8.7% increase from the previous year.
However, rising costs and shrinking profits have been concerning. The company anticipates ongoing challenges, particularly with tariffs impacting its operations. For instance, its gross margin decreased from 66.6% in Q3 2025 to 64.9% in Q3 2026, alongside declines in both operating margin and net income. Nevertheless, Medtronic offers a consistent dividend yield of 3.3%, having raised its payouts for 48 consecutive years, providing a safety net for investors during this challenging period.
Sanofi: Navigating Patent Pressures
Sanofi specializes in developing drug treatments across various therapeutic areas, including oncology, neurology, and immunology. Despite its extensive portfolio and promising pipeline, the company has faced difficulties in rewarding shareholders. Concerns surrounding the potential loss of patent protection for Dupixent, a key revenue driver, have contributed to stock price volatility. In 2025, Dupixent sales surged by 32.2%, generating 4.2 billion euros, but uncertainties linger.
The leadership transition within Sanofi, with a new CEO expected to take the helm, adds another layer of complexity. To offset potential revenue losses from Dupixent, the company aims for total sales growth in 2026, projecting a high-single-digit percentage increase compared to 2025. As investors await clearer progress, Sanofi offers a generous dividend yield of 5%, helping to mitigate some of the uncertainties surrounding the stock.
Bristol Myers Squibb: A Mixed Outlook
Bristol Myers Squibb has experienced fluctuations in its stock performance, with a modest increase this year but a decline of around 10% over the past five years. One of the primary concerns is the decreasing revenue from its legacy portfolio, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Additionally, the blood thinner Eliquis, which generated $14.4 billion in revenue in 2025, is approaching a patent cliff, raising further concerns.
Despite these challenges, Bristol Myers is witnessing positive developments in its growth portfolio, which includes several high-performing drugs. Revenue from this segment increased from $22.6 billion in 2024 to $26.4 billion in 2025. Although a slight revenue decline is expected in 2026, the company continues to offer a dividend yield of 4.2%. Overall, Bristol is considered a strong investment option among the three, given its recent momentum and growth potential.
Investment Considerations
Investors considering healthcare stocks during uncertain times should keep an eye on dividend yields, as they can provide a reliable income stream while awaiting market recoveries. The three companies discussed—Medtronic, Sanofi, and Bristol Myers Squibb—offer dividends that reflect their commitment to shareholders despite facing varying degrees of operational challenges.
Key Takeaways
- Medtronic offers a stable dividend yield of 3.3% and has a long history of increasing payouts.
- Sanofi’s 5% dividend yield provides a buffer as the company navigates patent concerns and leadership changes.
- Bristol Myers Squibb, with a dividend yield of 4.2%, shows promise through its growth portfolio, despite legacy revenue declines.
In conclusion, while the healthcare sector faces its share of challenges, these companies demonstrate resilience through their dividend offerings. Investors can benefit from these yields as they wait for a potential recovery in stock prices, positioning themselves for future growth.
Read more → www.fool.com